Which surgery monitor saves kidneys best? new trial aims to find out
NCT ID NCT07609680
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study compares two methods of managing blood flow during colorectal surgery: one guided by blood pressure and the other by how much blood the heart pumps. The goal is to see which approach better protects kidney function after surgery. Sixty adults with normal kidney function are being randomly assigned to one of the two methods.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If this trial succeeds, it could show that using cardiac index to guide fluid and medication during surgery better protects kidneys than standard blood pressure monitoring.
- What could go wrong
- This is a small, early-stage study with only 60 patients, so results may not apply to everyone. The difference between the two strategies might be small or not clinically meaningful.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 60 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jun 2026
- Expected to finish
-
Dec 2027
An estimate. End dates often move.
- Lead sponsor
-
A government agency
The lead sponsor is a government body.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 80 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Patients aged 18 to 80 years * Patients with American Society of Anesthesiologists physical status II-III * Patients with estimated glomerular filtration rate ≥60 mL/min/1.73 m² * Patients scheduled for colorectal surgery * Patients who provide written informed consent Exclusion Criteria: * Patients younger than 18 years or older than 80 years * Patients with estimated glomerular filtration rate \<60 mL/min/1.73 m² * Patients with American Society of Anesthesiologists physical status other than II-III * Patients who refuse to participate in the study * Patients who withdraw consent at any stage of the study
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Colorectal cancer are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Ankara Etlik City Hospital
RECRUITINGAnkara, Yenimahalle\Ankara, 06170, Turkey (Türkiye)
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Gut bacteria may hold clues to why some cancer treatments work better
- Burning the edges: a new way to stop colon polyps from coming back
- Missed Follow-Up colonoscopies: do they raise the risk of advanced growths?
- A 2.2 mm scope could spot cancerous tissue in minutes, not days
- The gatekeepers of tumors: scientists probe how blood vessels let immune cells in
- New Antibody-Drug conjugate put to the test against Hard-to-Treat cancers